OXGR1 - 2-oxoglutarate receptor | Elisa - Clia - Antibody - Protein

Background

The 2-Oxoglutarate Receptor 1 (OXGR1) is a G protein-coupled receptor (GPCR) that responds to 2-oxoglutarate (2-OG), also known as alpha-ketoglutarate, a key intermediate in cellular metabolism. Was a recently identified GPCR that responds to 2-oxoglutarate, a metabolite involved in cellular energy metabolism In summary, the 2-Oxoglutarate Receptor 1 (OXGR1) is a GPCR that responds to 2-oxoglutarate, a metabolite involved in cellular metabolism. OXGR1 regulates metabolic processes, glucose homeostasis, and renal function, and dysregulation of OXGR1 signaling is implicated in metabolic disorders and renal diseasesand amino acid metabolism. OXGR1 is expressed in various tissues, including the liver, kidney, brain, and gastrointestinal tract, where it regulates metabolic and physiological processes. OXGR1 is activated by 2-oxoglutarate (2-OG), which serves as an endogenous ligand for the receptor.

Structural Features:

• OXGR1 is a typical GPCR with seven transmembrane domains, an extracellular N-terminus, and an intracellular C-terminus.
• Its structure and signaling mechanisms are still being elucidated.

Physiological Functions:

• Metabolism Regulation: OXGR1 activation modulates metabolic pathways involved in energy production, amino acid metabolism, and cellular homeostasis.
• Glucose Homeostasis: OXGR1 may play roles in glucose homeostasis and insulin sensitivity, although its specific functions in glucose metabolism are still under investigation.
• Renal Function: OXGR1 is expressed in the kidney and may regulate renal function, electrolyte balance, and fluid homeostasis.

Clinical Implications:

• Metabolic Disorders: Dysregulation of OXGR1 signaling has been implicated in metabolic disorders such as obesity, diabetes, and metabolic syndrome.
• Renal Diseases: Alterations in OXGR1 expression or function may contribute to renal diseases such as chronic kidney disease (CKD) and diabetic nephropathy.

Therapeutic Potential:

• Drug Development: OXGR1 agonists and antagonists are being investigated for their potential therapeutic applications in metabolic disorders and renal diseases.
• Precision Medicine: Targeting OXGR1 signaling pathways may offer personalized treatment strategies for individuals with metabolic disorders or renal diseases.